News zum Sektor Gesundheit aus Asien

 

The HSI ended the day up 149 points or 0.6% at 26,085. The HSCEI rose 91 points or 1% to close at 9,198. The HSTECH climbed 47 points or 0.8%, closing at 5,662. The total market turnover for the day amounted to HKD210.473 billion.Hang Seng Indexes Company is set to make constituent changes after the bell. INNOVENT BIO (01801.HK)......

BEIJING (dpa-AFX) - Ascentage Pharma Group International (AAPG, 6855.HK) announced that it received clearance from both the US Food and Drug Administration (FDA) and the European Medicines Agency ......

At close, HSI rose 149 pts or 0.6% to 26,085. HSTI rose 47 pts or 0.8% to 5,662. HSCEI gained 91 pts or 1.0% to 9,198. Market turnover reached $210.47 billion.Active Heavyweights:PING AN (02318.HK) closed at $60.45, up 6.7%XIAOMI (01810.HK) closed at $42.78, up 1.9%MEITUAN (03690.HK) closed at $99.05, up 1%CCB (00939.HK) closed ......

Stock | Investment Rating | Potential Upside to Target PriceAlibaba (BABA.US) | Overweight | 27.1%YANGTZE POWER (600900.SH) | Overweight | 24.3%CONTEMPORARY AMPEREX (300750.SZ) | Overweight | 31.3%DUALITYBIO-B (09606.HK) | Overweight | 42.7%ESPRESSIF (688018.SH) | Overweight | 31.5%HKEX (00388.HK) | Overweight | 23.6%HKT-SS (068......

In October 2025, INNOVENT BIO (01801.HK) announced a global strategic partnership with Takeda Pharmaceutical (4502.JP). This partnership involves a licensing agreement valued at USD11.4 billion and a USD100 million strategic equity investment from Takeda.INNOVENT BIO announced that all conditions precedent to each of the license......

BEIJING (dpa-AFX) - Innovent Biologics (IVBXF, 1801.HK) announced that its global strategic collaboration with Takeda (4502.T, TAK) has officially closed and become effective following the satisfa......

The HSI opened 102 points or 0.4% lower at 25,833. The HSCEI dipped 29 points or 0.3% to 9,077. The HSTECH dropped 23 points or 0.4% to 5,592.Hang Seng Indexes Company is set to make constituent changes after the bell. INNOVENT BIO (01801.HK), which will be added to the HSI next week, opened 0.2% higher. LEAPMOTOR (09863.HK), po......

ALI HEALTH (00241.HK) has announced a strategic cooperation with Beijing Tong Ren Tang.According to the agreement, their cooperation will focus on Beijing Tong Ren Tang's Angong Niuhuang Wan series products, integrating Tong Ren Tang's pharmaceutical expertise with ALI HEALTH's digital platform services to jointly bu......

ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Phase III study (POLARIS-1; NCT06051409) of its compound under investigation, olverembatinib, in combination with chemotherapy for the treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As the second global registrational Phase III study of olverembatinib that has been cleared by regulators in the US and Europe, the POLARIS-1 study is simultaneously enrolling patients across trial centers in multiple countries in order to accelerate olverembatinib's...

SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The......

The basal cell carcinoma market is anticipated to experience a positive shift due to the better uptake of existing drugs, the expected market launch of new therapies such as Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix......

Cresent Biopharma shares were trading higher Thursday but have since reversed and begun trading lower after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical. read more...

OTTAWA (dpa-AFX) - At 7:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global markets and Greater China...

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China...

STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's Disease (CTAD) conference, held in San Diego......

The HSI concluded the midday up 48 points or 0.2% at 25,809. The HSCEI rose 34 points or 0.4% to 9,062. The HSTECH climbed 32 points or 0.6% to 5,567. The total half-day turnover for the market amounted to HKD92.278 billion.In the FTSE China 50 Index review, CHINAHONGQIAO (01378.HK), CATL (03750.HK), and HENGRUI PHARMA (01276.HK......

WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in early Alzheimer's disease at t......

The HSI opened 43 points or 0.2% higher at 25,804. The HSCEI climbed 23 points or 0.3% to 9,051. The HSTECH rose 11 points or 0.2% to 5,546.In the FTSE China 50 Index review, CHINAHONGQIAO (01378.HK), CATL (03750.HK), and HENGRUI PHARMA (01276.HK) were included, while CSC (06066.HK), GWMOTOR (02333.HK), and LI AUTO-W (02015.HK) ......